img

Global Hereditary Angioedema Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Hereditary Angioedema Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adultsthe C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.
The global Hereditary Angioedema Drug market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Hereditary Angioedema Drug is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Hereditary Angioedema Drug is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Hereditary Angioedema Drug is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Hereditary Angioedema Drug include Pharming Group NV, Takeda, CSL Limited, IBio Inc., BioCryst Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Hereditary Angioedema Drug, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Hereditary Angioedema Drug by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Hereditary Angioedema Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Hereditary Angioedema Drug market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
By Type
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Hereditary Angioedema Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Hereditary Angioedema Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hereditary Angioedema Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Hereditary Angioedema Drug Definition
1.2 Market by Type
1.2.1 Global Hereditary Angioedema Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 C1 Esterase Inhibitor
1.2.3 Kallikrein Inhibitor
1.2.4 Selective Bradykinin B2 Receptor Antagonist
1.3 Market Segment by Application
1.3.1 Global Hereditary Angioedema Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Hereditary Angioedema Drug Sales
2.1 Global Hereditary Angioedema Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Hereditary Angioedema Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Hereditary Angioedema Drug Revenue by Region
2.3.1 Global Hereditary Angioedema Drug Revenue by Region (2018-2023)
2.3.2 Global Hereditary Angioedema Drug Revenue by Region (2024-2034)
2.4 Global Hereditary Angioedema Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Hereditary Angioedema Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Hereditary Angioedema Drug Sales Quantity by Region
2.6.1 Global Hereditary Angioedema Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Hereditary Angioedema Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Hereditary Angioedema Drug Sales Quantity by Manufacturers
3.1.1 Global Hereditary Angioedema Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Hereditary Angioedema Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Hereditary Angioedema Drug Sales in 2024
3.2 Global Hereditary Angioedema Drug Revenue by Manufacturers
3.2.1 Global Hereditary Angioedema Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Hereditary Angioedema Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Hereditary Angioedema Drug Revenue in 2024
3.3 Global Hereditary Angioedema Drug Sales Price by Manufacturers
3.4 Global Key Players of Hereditary Angioedema Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Hereditary Angioedema Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Hereditary Angioedema Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Hereditary Angioedema Drug, Product Offered and Application
3.8 Global Key Manufacturers of Hereditary Angioedema Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Hereditary Angioedema Drug Sales Quantity by Type
4.1.1 Global Hereditary Angioedema Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Hereditary Angioedema Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Hereditary Angioedema Drug Revenue by Type
4.2.1 Global Hereditary Angioedema Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Hereditary Angioedema Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Hereditary Angioedema Drug Revenue Market Share by Type (2018-2034)
4.3 Global Hereditary Angioedema Drug Price by Type
4.3.1 Global Hereditary Angioedema Drug Price by Type (2018-2023)
4.3.2 Global Hereditary Angioedema Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Hereditary Angioedema Drug Sales Quantity by Application
5.1.1 Global Hereditary Angioedema Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Hereditary Angioedema Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Hereditary Angioedema Drug Revenue by Application
5.2.1 Global Hereditary Angioedema Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Hereditary Angioedema Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Hereditary Angioedema Drug Revenue Market Share by Application (2018-2034)
5.3 Global Hereditary Angioedema Drug Price by Application
5.3.1 Global Hereditary Angioedema Drug Price by Application (2018-2023)
5.3.2 Global Hereditary Angioedema Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Hereditary Angioedema Drug Sales by Company
6.1.1 North America Hereditary Angioedema Drug Revenue by Company (2018-2023)
6.1.2 North America Hereditary Angioedema Drug Sales Quantity by Company (2018-2023)
6.2 North America Hereditary Angioedema Drug Market Size by Type
6.2.1 North America Hereditary Angioedema Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Hereditary Angioedema Drug Revenue by Type (2018-2034)
6.3 North America Hereditary Angioedema Drug Market Size by Application
6.3.1 North America Hereditary Angioedema Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Hereditary Angioedema Drug Revenue by Application (2018-2034)
6.4 North America Hereditary Angioedema Drug Market Size by Country
6.4.1 North America Hereditary Angioedema Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Hereditary Angioedema Drug Revenue by Country (2018-2034)
6.4.3 North America Hereditary Angioedema Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Hereditary Angioedema Drug Sales by Company
7.1.1 Europe Hereditary Angioedema Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Hereditary Angioedema Drug Revenue by Company (2018-2023)
7.2 Europe Hereditary Angioedema Drug Market Size by Type
7.2.1 Europe Hereditary Angioedema Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Hereditary Angioedema Drug Revenue by Type (2018-2034)
7.3 Europe Hereditary Angioedema Drug Market Size by Application
7.3.1 Europe Hereditary Angioedema Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Hereditary Angioedema Drug Revenue by Application (2018-2034)
7.4 Europe Hereditary Angioedema Drug Market Size by Country
7.4.1 Europe Hereditary Angioedema Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Hereditary Angioedema Drug Revenue by Country (2018-2034)
7.4.3 Europe Hereditary Angioedema Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Hereditary Angioedema Drug Sales by Company
8.1.1 China Hereditary Angioedema Drug Sales Quantity by Company (2018-2023)
8.1.2 China Hereditary Angioedema Drug Revenue by Company (2018-2023)
8.2 China Hereditary Angioedema Drug Market Size by Type
8.2.1 China Hereditary Angioedema Drug Sales Quantity by Type (2018-2034)
8.2.2 China Hereditary Angioedema Drug Revenue by Type (2018-2034)
8.3 China Hereditary Angioedema Drug Market Size by Application
8.3.1 China Hereditary Angioedema Drug Sales Quantity by Application (2018-2034)
8.3.2 China Hereditary Angioedema Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Hereditary Angioedema Drug Sales by Company
9.1.1 APAC Hereditary Angioedema Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Hereditary Angioedema Drug Revenue by Company (2018-2023)
9.2 APAC Hereditary Angioedema Drug Market Size by Type
9.2.1 APAC Hereditary Angioedema Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Hereditary Angioedema Drug Revenue by Type (2018-2034)
9.3 APAC Hereditary Angioedema Drug Market Size by Application
9.3.1 APAC Hereditary Angioedema Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Hereditary Angioedema Drug Revenue by Application (2018-2034)
9.4 APAC Hereditary Angioedema Drug Market Size by Region
9.4.1 APAC Hereditary Angioedema Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Hereditary Angioedema Drug Revenue by Region (2018-2034)
9.4.3 APAC Hereditary Angioedema Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Hereditary Angioedema Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Hereditary Angioedema Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Hereditary Angioedema Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Pharming Group NV
11.1.1 Pharming Group NV Company Information
11.1.2 Pharming Group NV Overview
11.1.3 Pharming Group NV Hereditary Angioedema Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Pharming Group NV Hereditary Angioedema Drug Products and Services
11.1.5 Pharming Group NV Hereditary Angioedema Drug SWOT Analysis
11.1.6 Pharming Group NV Recent Developments
11.2 Takeda
11.2.1 Takeda Company Information
11.2.2 Takeda Overview
11.2.3 Takeda Hereditary Angioedema Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Takeda Hereditary Angioedema Drug Products and Services
11.2.5 Takeda Hereditary Angioedema Drug SWOT Analysis
11.2.6 Takeda Recent Developments
11.3 CSL Limited
11.3.1 CSL Limited Company Information
11.3.2 CSL Limited Overview
11.3.3 CSL Limited Hereditary Angioedema Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 CSL Limited Hereditary Angioedema Drug Products and Services
11.3.5 CSL Limited Hereditary Angioedema Drug SWOT Analysis
11.3.6 CSL Limited Recent Developments
11.4 IBio Inc.
11.4.1 IBio Inc. Company Information
11.4.2 IBio Inc. Overview
11.4.3 IBio Inc. Hereditary Angioedema Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 IBio Inc. Hereditary Angioedema Drug Products and Services
11.4.5 IBio Inc. Hereditary Angioedema Drug SWOT Analysis
11.4.6 IBio Inc. Recent Developments
11.5 BioCryst Pharmaceuticals, Inc.
11.5.1 BioCryst Pharmaceuticals, Inc. Company Information
11.5.2 BioCryst Pharmaceuticals, Inc. Overview
11.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Products and Services
11.5.5 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug SWOT Analysis
11.5.6 BioCryst Pharmaceuticals, Inc. Recent Developments
11.6 Ionis Pharmaceuticals, Inc.
11.6.1 Ionis Pharmaceuticals, Inc. Company Information
11.6.2 Ionis Pharmaceuticals, Inc. Overview
11.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Products and Services
11.6.5 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug SWOT Analysis
11.6.6 Ionis Pharmaceuticals, Inc. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Hereditary Angioedema Drug Value Chain Analysis
12.2 Hereditary Angioedema Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hereditary Angioedema Drug Production Mode & Process
12.4 Hereditary Angioedema Drug Sales and Marketing
12.4.1 Hereditary Angioedema Drug Sales Channels
12.4.2 Hereditary Angioedema Drug Distributors
12.5 Hereditary Angioedema Drug Customers
13 Market Dynamics
13.1 Hereditary Angioedema Drug Industry Trends
13.2 Hereditary Angioedema Drug Market Drivers
13.3 Hereditary Angioedema Drug Market Challenges
13.4 Hereditary Angioedema Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of C1 Esterase Inhibitor
Table 3. Major Manufacturers of Kallikrein Inhibitor
Table 4. Major Manufacturers of Selective Bradykinin B2 Receptor Antagonist
Table 5. Global Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Hereditary Angioedema Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Hereditary Angioedema Drug Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Hereditary Angioedema Drug Revenue Market Share by Region (2018-2023)
Table 9. Global Hereditary Angioedema Drug Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Hereditary Angioedema Drug Revenue Market Share by Region (2024-2034)
Table 11. Global Hereditary Angioedema Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 12. Global Hereditary Angioedema Drug Sales by Region (2018-2023) & (K Units)
Table 13. Global Hereditary Angioedema Drug Sales Market Share by Region (2018-2023)
Table 14. Global Hereditary Angioedema Drug Sales by Region (2024-2034) & (K Units)
Table 15. Global Hereditary Angioedema Drug Sales Market Share by Region (2024-2034)
Table 16. Global Hereditary Angioedema Drug Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 17. Global Hereditary Angioedema Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 18. Global Hereditary Angioedema Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Hereditary Angioedema Drug Revenue Share by Manufacturers (2018-2023)
Table 20. Global Hereditary Angioedema Drug Price by Manufacturers 2018-2023 (USD/Unit)
Table 21. Global Key Players of Hereditary Angioedema Drug, Industry Ranking, 2021 VS 2024
Table 22. Global Hereditary Angioedema Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Hereditary Angioedema Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hereditary Angioedema Drug as of 2024)
Table 24. Global Key Manufacturers of Hereditary Angioedema Drug, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Hereditary Angioedema Drug, Product Offered and Application
Table 26. Global Key Manufacturers of Hereditary Angioedema Drug, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 29. Global Hereditary Angioedema Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 30. Global Hereditary Angioedema Drug Sales Quantity Share by Type (2018-2023)
Table 31. Global Hereditary Angioedema Drug Sales Quantity Share by Type (2024-2034)
Table 32. Global Hereditary Angioedema Drug Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Hereditary Angioedema Drug Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Hereditary Angioedema Drug Revenue Share by Type (2018-2023)
Table 35. Global Hereditary Angioedema Drug Revenue Share by Type (2024-2034)
Table 36. Hereditary Angioedema Drug Price by Type (2018-2023) & (USD/Unit)
Table 37. Global Hereditary Angioedema Drug Price Forecast by Type (2024-2034) & (USD/Unit)
Table 38. Global Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 39. Global Hereditary Angioedema Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 40. Global Hereditary Angioedema Drug Sales Quantity Share by Application (2018-2023)
Table 41. Global Hereditary Angioedema Drug Sales Quantity Share by Application (2024-2034)
Table 42. Global Hereditary Angioedema Drug Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Hereditary Angioedema Drug Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Hereditary Angioedema Drug Revenue Share by Application (2018-2023)
Table 45. Global Hereditary Angioedema Drug Revenue Share by Application (2024-2034)
Table 46. Hereditary Angioedema Drug Price by Application (2018-2023) & (USD/Unit)
Table 47. Global Hereditary Angioedema Drug Price Forecast by Application (2024-2034) & (USD/Unit)
Table 48. North America Hereditary Angioedema Drug Revenue by Company (2018-2023) & (US$ Million)
Table 49. North America Hereditary Angioedema Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 50. North America Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 51. North America Hereditary Angioedema Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 52. North America Hereditary Angioedema Drug Revenue by Type (2018-2023) & (US$ Million)
Table 53. North America Hereditary Angioedema Drug Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 55. North America Hereditary Angioedema Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 56. North America Hereditary Angioedema Drug Revenue by Application (2018-2023) & (US$ Million)
Table 57. North America Hereditary Angioedema Drug Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Hereditary Angioedema Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 59. North America Hereditary Angioedema Drug Revenue by Country (2018-2023) & (US$ Million)
Table 60. North America Hereditary Angioedema Drug Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Hereditary Angioedema Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 62. North America Hereditary Angioedema Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 63. Europe Hereditary Angioedema Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 64. Europe Hereditary Angioedema Drug Revenue by Company (2018-2023) & (US$ Million)
Table 65. Europe Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 66. Europe Hereditary Angioedema Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 67. Europe Hereditary Angioedema Drug Revenue by Type (2018-2023) & (US$ Million)
Table 68. Europe Hereditary Angioedema Drug Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Europe Hereditary Angioedema Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 71. Europe Hereditary Angioedema Drug Revenue by Application (2018-2023) & (US$ Million)
Table 72. Europe Hereditary Angioedema Drug Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Hereditary Angioedema Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 74. Europe Hereditary Angioedema Drug Revenue by Country (2018-2023) & (US$ Million)
Table 75. Europe Hereditary Angioedema Drug Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Hereditary Angioedema Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 77. Europe Hereditary Angioedema Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 78. China Hereditary Angioedema Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 79. China Hereditary Angioedema Drug Revenue by Company (2018-2023) & (US$ Million)
Table 80. China Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 81. China Hereditary Angioedema Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 82. China Hereditary Angioedema Drug Revenue by Type (2018-2023) & (US$ Million)
Table 83. China Hereditary Angioedema Drug Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 85. China Hereditary Angioedema Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 86. China Hereditary Angioedema Drug Revenue by Application (2018-2023) & (US$ Million)
Table 87. China Hereditary Angioedema Drug Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Hereditary Angioedema Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 89. APAC Hereditary Angioedema Drug Revenue by Company (2018-2023) & (US$ Million)
Table 90. APAC Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 91. APAC Hereditary Angioedema Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 92. APAC Hereditary Angioedema Drug Revenue by Type (2018-2023) & (US$ Million)
Table 93. APAC Hereditary Angioedema Drug Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 95. APAC Hereditary Angioedema Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 96. APAC Hereditary Angioedema Drug Revenue by Application (2018-2023) & (US$ Million)
Table 97. APAC Hereditary Angioedema Drug Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Hereditary Angioedema Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 99. APAC Hereditary Angioedema Drug Revenue by Region (2018-2023) & (US$ Million)
Table 100. APAC Hereditary Angioedema Drug Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Hereditary Angioedema Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 102. APAC Hereditary Angioedema Drug Sales Quantity by Region (2024-2034) & (K Units)
Table 103. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 104. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Company (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Type (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Application (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Country (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 117. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 118. Pharming Group NV Company Information
Table 119. Pharming Group NV Description and Overview
Table 120. Pharming Group NV Hereditary Angioedema Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 121. Pharming Group NV Hereditary Angioedema Drug Product and Services
Table 122. Pharming Group NV Hereditary Angioedema Drug SWOT Analysis
Table 123. Pharming Group NV Recent Developments
Table 124. Takeda Company Information
Table 125. Takeda Description and Overview
Table 126. Takeda Hereditary Angioedema Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 127. Takeda Hereditary Angioedema Drug Product and Services
Table 128. Takeda Hereditary Angioedema Drug SWOT Analysis
Table 129. Takeda Recent Developments
Table 130. CSL Limited Company Information
Table 131. CSL Limited Description and Overview
Table 132. CSL Limited Hereditary Angioedema Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 133. CSL Limited Hereditary Angioedema Drug Product and Services
Table 134. CSL Limited Hereditary Angioedema Drug SWOT Analysis
Table 135. CSL Limited Recent Developments
Table 136. IBio Inc. Company Information
Table 137. IBio Inc. Description and Overview
Table 138. IBio Inc. Hereditary Angioedema Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 139. IBio Inc. Hereditary Angioedema Drug Product and Services
Table 140. IBio Inc. Hereditary Angioedema Drug SWOT Analysis
Table 141. IBio Inc. Recent Developments
Table 142. BioCryst Pharmaceuticals, Inc. Company Information
Table 143. BioCryst Pharmaceuticals, Inc. Description and Overview
Table 144. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 145. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
Table 146. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug SWOT Analysis
Table 147. BioCryst Pharmaceuticals, Inc. Recent Developments
Table 148. Ionis Pharmaceuticals, Inc. Company Information
Table 149. Ionis Pharmaceuticals, Inc. Description and Overview
Table 150. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 151. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
Table 152. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug SWOT Analysis
Table 153. Ionis Pharmaceuticals, Inc. Recent Developments
Table 154. Key Raw Materials Lists
Table 155. Raw Materials Key Suppliers Lists
Table 156. Hereditary Angioedema Drug Distributors List
Table 157. Hereditary Angioedema Drug Customers List
Table 158. Hereditary Angioedema Drug Market Trends
Table 159. Hereditary Angioedema Drug Market Drivers
Table 160. Hereditary Angioedema Drug Market Challenges
Table 161. Hereditary Angioedema Drug Market Restraints
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources
List of Figures
Figure 1. Hereditary Angioedema Drug Product Picture
Figure 2. Global Hereditary Angioedema Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Hereditary Angioedema Drug Market Share by Type in 2024 & 2034
Figure 4. C1 Esterase Inhibitor Product Picture
Figure 5. Kallikrein Inhibitor Product Picture
Figure 6. Selective Bradykinin B2 Receptor Antagonist Product Picture
Figure 7. Global Hereditary Angioedema Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 8. Global Hereditary Angioedema Drug Market Share by Application in 2024 & 2034
Figure 9. Retail Pharmacies
Figure 10. Hospital Pharmacies
Figure 11. Online Pharmacies
Figure 12. Hereditary Angioedema Drug Report Years Considered
Figure 13. Global Hereditary Angioedema Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 14. Global Hereditary Angioedema Drug Revenue 2018-2034 (US$ Million)
Figure 15. Global Hereditary Angioedema Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 16. Global Hereditary Angioedema Drug Sales Quantity 2018-2034 (K Units)
Figure 17. Global Hereditary Angioedema Drug Sales Quantity Market Share by Region (2018-2023)
Figure 18. Global Hereditary Angioedema Drug Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America Hereditary Angioedema Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 20. North America Hereditary Angioedema Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Hereditary Angioedema Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. Europe Hereditary Angioedema Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Hereditary Angioedema Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. China Hereditary Angioedema Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC Hereditary Angioedema Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. APAC Hereditary Angioedema Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Hereditary Angioedema Drug Sales Quantity in 2024
Figure 30. The Top 10 and Top 5 Players Market Share by Hereditary Angioedema Drug Revenue in 2024
Figure 31. Hereditary Angioedema Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 32. Global Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global Hereditary Angioedema Drug Revenue Market Share by Type (2018-2034)
Figure 34. Global Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global Hereditary Angioedema Drug Revenue Market Share by Application (2018-2034)
Figure 36. North America Hereditary Angioedema Drug Revenue Market Share by Company in 2024
Figure 37. North America Hereditary Angioedema Drug Sales Quantity Market Share by Company in 2024
Figure 38. North America Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America Hereditary Angioedema Drug Revenue Market Share by Type (2018-2034)
Figure 40. North America Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America Hereditary Angioedema Drug Revenue Market Share by Application (2018-2034)
Figure 42. North America Hereditary Angioedema Drug Revenue Share by Country (2018-2034)
Figure 43. North America Hereditary Angioedema Drug Sales Quantity Share by Country (2018-2034)
Figure 44. U.S. Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Hereditary Angioedema Drug Sales Quantity Market Share by Company in 2024
Figure 47. Europe Hereditary Angioedema Drug Revenue Market Share by Company in 2024
Figure 48. Europe Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe Hereditary Angioedema Drug Revenue Market Share by Type (2018-2034)
Figure 50. Europe Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe Hereditary Angioedema Drug Revenue Market Share by Application (2018-2034)
Figure 52. Europe Hereditary Angioedema Drug Revenue Share by Country (2018-2034)
Figure 53. Europe Hereditary Angioedema Drug Sales Quantity Share by Country (2018-2034)
Figure 54. Germany Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 55. France Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 57. Italy Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Russia Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 59. China Hereditary Angioedema Drug Sales Quantity Market Share by Company in 2024
Figure 60. China Hereditary Angioedema Drug Revenue Market Share by Company in 2024
Figure 61. China Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2034)
Figure 62. China Hereditary Angioedema Drug Revenue Market Share by Type (2018-2034)
Figure 63. China Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2034)
Figure 64. China Hereditary Angioedema Drug Revenue Market Share by Application (2018-2034)
Figure 65. APAC Hereditary Angioedema Drug Sales Quantity Market Share by Company in 2024
Figure 66. APAC Hereditary Angioedema Drug Revenue Market Share by Company in 2024
Figure 67. APAC Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC Hereditary Angioedema Drug Revenue Market Share by Type (2018-2034)
Figure 69. APAC Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC Hereditary Angioedema Drug Revenue Market Share by Application (2018-2034)
Figure 71. APAC Hereditary Angioedema Drug Revenue Share by Region (2018-2034)
Figure 72. APAC Hereditary Angioedema Drug Sales Quantity Share by Region (2018-2034)
Figure 73. Japan Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 77. India Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity Market Share by Company in 2024
Figure 79. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue Market Share by Company in 2024
Figure 80. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Quantity Share by Country (2018-2034)
Figure 85. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue Share by Country (2018-2034)
Figure 86. Brazil Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 87. Mexico Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Turkey Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Israel Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 90. GCC Countries Hereditary Angioedema Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Hereditary Angioedema Drug Value Chain
Figure 92. Hereditary Angioedema Drug Production Process
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries